{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T11:44:18Z","timestamp":1776512658540,"version":"3.51.2"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T00:00:00Z","timestamp":1677110400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T00:00:00Z","timestamp":1677110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1245\/s10434-023-13242-8","type":"journal-article","created":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T15:03:13Z","timestamp":1677164593000},"page":"3287-3299","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Role of Hyperthermic Intraperitoneal Chemotherapy Combined with Cytoreductive Surgery as Consolidation Therapy for Advanced Epithelial Ovarian Cancer"],"prefix":"10.1245","volume":"30","author":[{"given":"Lisa","family":"Frankinet","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aditi","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Alcazer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Marc","family":"Classe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Marc","family":"Bereder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Meeus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christophe","family":"Pomel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francois","family":"Mithieux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karine","family":"Abboud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Romauld","family":"Wermert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Lavoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederic","family":"Marchal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Glehen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoual","family":"Bakrin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,2,23]]},"reference":[{"issue":"5","key":"13242_CR1","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1200\/JCO.2002.20.5.1248","volume":"20","author":"RE Bristow","year":"2002","unstructured":"Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002;20(5):1248\u201359.","journal-title":"J Clin Oncol"},{"issue":"3","key":"13242_CR2","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1093\/jnci\/djj019","volume":"98","author":"CC Earle","year":"2006","unstructured":"Earle CC, Schrag D, Neville BA, Yabroff KR, Topor M, Fahey A, et al. Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients. J Natl Cancer Inst. 2006;98(3):172\u201380. https:\/\/doi.org\/10.1093\/jnci\/djj019.","journal-title":"J Natl Cancer Inst"},{"issue":"24","key":"13242_CR3","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1056\/NEJMoa041125","volume":"351","author":"PG Rose","year":"2004","unstructured":"Rose PG, Nerenstone S, Brady MF, Clarke-Pearson D, Olt G, Rubin SC, Gynecologic Oncology Group, et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med. 2004;351(24):2489\u201397. https:\/\/doi.org\/10.1056\/NEJMoa041125.","journal-title":"N Engl J Med"},{"issue":"5","key":"13242_CR4","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1034\/j.1600-0412.2001.080005432.x","volume":"80","author":"A Obermair","year":"2001","unstructured":"Obermair A, Sevelda P. Impact of second look laparotomy and secondary cytoreductive surgery at second-look laparotomy in ovarian cancer patients. Acta Obstet Gynecol Scand. 2001;80(5):432\u20136.","journal-title":"Acta Obstet Gynecol Scand"},{"key":"13242_CR5","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ygyno.2005.05.012","volume":"99","author":"BE Greer","year":"2005","unstructured":"Greer BE, Bundy BN, Ozols RF, et al. Implications of second-look laparotomy in the context of optimally resected Stage III ovarian cancer: a nonrandomized comparison using an explanatory analysis: a GOG study. Gynecol Oncol. 2005;99:71\u20139.","journal-title":"Gynecol Oncol"},{"issue":"24","key":"13242_CR6","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.1056\/NEJMe048292","volume":"351","author":"T Thigpen","year":"2004","unstructured":"Thigpen T. The if and when of surgical debulking for ovarian carcinoma. N Engl J Med. 2004;351(24):2544\u20136. https:\/\/doi.org\/10.1056\/NEJMe048292.","journal-title":"N Engl J Med"},{"key":"13242_CR7","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/j.1048-891X.2005.15003.x","volume":"15","author":"J Rahaman","year":"2005","unstructured":"Rahaman J, Dottino P, Jennings TS, et al. The second-look operation improves survival in suboptimally debulked stage III ovarian cancer patients. Int J Gynecol Cancer. 2005;15:19\u201325.","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"13242_CR8","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/s0090-8258(03)00474-8","volume":"91","author":"C Tournigand","year":"2003","unstructured":"Tournigand C, Louvet C, Molitor JL, Fritel X, Dehni N, Sezeur A, et al. Long-term survival with consolidation intraperitoneal chemotherapy for patients with advanced ovarian cancer with pathological complete remission. Gynecol Oncol. 2003;91(2):341\u20135. https:\/\/doi.org\/10.1016\/s0090-8258(03)00474-8.","journal-title":"Gynecol Oncol."},{"issue":"1","key":"13242_CR9","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ygyno.2009.03.018","volume":"114","author":"DS Chi","year":"2009","unstructured":"Chi DS, Eisenhauer EL, Zivanovic O, Sonoda Y, Abu-Rustum NR, Levine DA, et al. Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol. 2009;114(1):26\u201331. https:\/\/doi.org\/10.1016\/j.ygyno.2009.03.018.","journal-title":"Gynecol Oncol"},{"issue":"9","key":"13242_CR10","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.3390\/cancers12092414","volume":"12","author":"T Reverdy","year":"2020","unstructured":"Reverdy T, Sajous C, P\u00e9ron J, Glehen O, Bakrin N, Gertych W, et al. Front-line maintenance therapy in advanced ovarian cancer-current advances and perspectives. Cancers. 2020;12(9):2414. https:\/\/doi.org\/10.3390\/cancers12092414.","journal-title":"Cancers"},{"issue":"3","key":"13242_CR11","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1056\/NEJMoa1708618","volume":"378","author":"WJ van Driel","year":"2018","unstructured":"van Driel WJ, Koole SN, Sikorska K, Schagen van Leeuwen JH, Schreuder HWR, Hermans RHM, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med. 2018;378(3):230\u201340. https:\/\/doi.org\/10.1056\/NEJMoa1708618.","journal-title":"N Engl J Med"},{"issue":"2","key":"13242_CR12","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s00280-017-3376-8","volume":"80","author":"AA Mendivil","year":"2017","unstructured":"Mendivil AA, Rettenmaier MA, Abaid LN, Brown JV 3rd, Mori KM, Lopez KL, et al. Consolidation hyperthermic intraperitoneal chemotherapy for the treatment of advanced stage ovarian carcinoma: a 3 year experience. Cancer Chemother Pharmacol. 2017;80(2):405\u201310. https:\/\/doi.org\/10.1007\/s00280-017-3376-8.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"13242_CR13","doi-asserted-by":"publisher","first-page":"437","DOI":"10.5468\/ogs.21093","volume":"64","author":"J Ko","year":"2021","unstructured":"Ko J, Ha HI, Choi MC, Jung SG, Park H, Joo WD, et al. Hyperthermic intraperitoneal chemotherapy as consolidation treatment of advanced stage ovarian cancer. Obstet Gynecol Sci. 2021;64(5):437\u201343. https:\/\/doi.org\/10.5468\/ogs.21093.","journal-title":"Obstet Gynecol Sci"},{"issue":"12","key":"13242_CR14","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1016\/j.ejso.2013.09.030","volume":"39","author":"N Bakrin","year":"2013","unstructured":"Bakrin N, Bereder JM, Decullier E, Classe JM, Msika S, Lorimier G, et al. Peritoneal carcinomatosis treated with cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for advanced ovarian carcinoma: a French multicentre retrospective cohort study of 566 patients. Eur J Surg Oncol. 2013;39(12):1435\u201343. https:\/\/doi.org\/10.1016\/j.ejso.2013.09.030.","journal-title":"Eur J Surg Oncol"},{"key":"13242_CR15","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/978-1-4613-1247-5_23","volume":"82","author":"P Jacquet","year":"1996","unstructured":"Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res. 1996;82:359\u201374. https:\/\/doi.org\/10.1007\/978-1-4613-1247-5_23.","journal-title":"Cancer Treat Res"},{"key":"13242_CR16","series-title":"Textbook and Video Atlas","first-page":"1","volume-title":"Cytoreductive surgery & perioperative chemotherapy for peritoneal surface malignancy","author":"PH Sugarbaker","year":"2012","unstructured":"Sugarbaker PH. An overview of peritonectomy, visceral resections, and perioperative chemotherapy for peritoneal surface malignancy. In: PH Sugarbaker, editor. Cytoreductive surgery & perioperative chemotherapy for peritoneal surface malignancy. Textbook and Video Atlas. Woodbury: Cine-Med Publishing; 2012. p. 1\u201330."},{"key":"13242_CR17","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/jso.21061","volume":"98","author":"O Glehen","year":"2008","unstructured":"Glehen O, Cotte E, Kusamura S, Deraco M, Baratti D, Passot G, et al. Hyperthermic intraperitoneal chemotherapy: Nomenclature and modalities of perfusion. J Surg Oncol. 2008;98:242\u20136. https:\/\/doi.org\/10.1002\/jso.21061.","journal-title":"J Surg Oncol."},{"key":"13242_CR18","volume-title":"Peritoneal carcinomatosis: principles of management","author":"PH Sugarbaker","year":"1996","unstructured":"Sugarbaker PH, Averbach AM, Jacquet P, et al. A simplified approach to hyperthermic intraoperative intraperitoneal chemotherapy (HIIC) using a self retaining retractor. In: PH Sugarbaker, editor., et al., Peritoneal carcinomatosis: principles of management. Boston: Springer; 1996."},{"issue":"2","key":"13242_CR19","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.ygyno.2016.05.032","volume":"142","author":"S Gouy","year":"2016","unstructured":"Gouy S, Ferron G, Glehen O, Bayar A, Marchal F, Pomel C, et al. Results of a multicenter phase I dose-finding trial of hyperthermic intraperitoneal cisplatin after neoadjuvant chemotherapy and complete cytoreductive surgery and followed by maintenance bevacizumab in initially unresectable ovarian cancer. Gynecol Oncol. 2016;142(2):237\u201342. https:\/\/doi.org\/10.1016\/j.ygyno.2016.05.032.","journal-title":"Gynecol Oncol"},{"issue":"2","key":"13242_CR20","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1515\/pp-2017-0003","volume":"2","author":"K Van der Speeten","year":"2017","unstructured":"Van der Speeten K, Lemoine L, Sugarbaker P. Overview of the optimal perioperative intraperitoneal chemotherapy regimens used in current clinical practice. Pleura Peritoneum. 2017;2(2):63\u201372. https:\/\/doi.org\/10.1515\/pp-2017-0003.","journal-title":"Pleura Peritoneum"},{"key":"13242_CR21","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1093\/annonc\/mdf019","volume":"13","author":"D Elias","year":"2002","unstructured":"Elias D, Bonnay M, Puizillou JM, et al. Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution. Ann Oncol. 2002;13:267\u201372.","journal-title":"Ann Oncol"},{"issue":"2","key":"13242_CR22","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1097\/SLA.0b013e3182263933","volume":"254","author":"F Quenet","year":"2011","unstructured":"Quenet F, Go\u00e9r\u00e9 D, Mehta S, Roca L, Dumont F, Hessissen M, et al. Results of two bi-institutional prospective studies using intraperitoneal oxaliplatin with or without irinotecan during HIPEC after cytoreductive surgery for colorectal carcinomatosis. Ann Surg. 2011;254(2):294\u2013301. https:\/\/doi.org\/10.1097\/SLA.0b013e3182263933.","journal-title":"Ann Surg"},{"key":"13242_CR23","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE). https:\/\/ctep.cancer.gov\u203a protocoldevelopment\u203a docs. Accessed 30 May 2022"},{"issue":"2","key":"13242_CR24","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1002\/jso.23626","volume":"110","author":"TA Aloia","year":"2014","unstructured":"Aloia TA, Zimmitti G, Conrad C, Gottumukalla V, Kopetz S, Vauthey JN. Return to intended oncologic treatment (RIOT): a novel metric for evaluating the quality of oncosurgical therapy for malignancy. J Surg Oncol. 2014;110(2):107\u201314. https:\/\/doi.org\/10.1002\/jso.23626.","journal-title":"J Surg Oncol"},{"issue":"2","key":"13242_CR25","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.ejso.2020.07.025","volume":"47","author":"U Joneborg","year":"2021","unstructured":"Joneborg U, Palsdottir K, Farm E, Johansson H, Salehi S. Time-interval to adjuvant chemotherapy and postoperative management after upper abdominal surgical procedures in advanced ovarian cancer. Eur J Surg Oncol. 2021;47(2):353\u20139. https:\/\/doi.org\/10.1016\/j.ejso.2020.07.025.","journal-title":"Eur J Surg Oncol"},{"issue":"6","key":"13242_CR26","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1093\/jjco\/hyn034","volume":"38","author":"HS Kim","year":"2008","unstructured":"Kim HS, Park NH, Chung HH, Kim JW, Song YS, Kang SB. Are three additional cycles of chemotherapy useful in patients with advanced-stage epithelial ovarian cancer after a complete response to six cycles of intravenous adjuvant paclitaxel and carboplatin? Jpn J Clin Oncol. 2008;38(6):445\u201350. https:\/\/doi.org\/10.1093\/jjco\/hyn034.","journal-title":"Jpn J Clin Oncol"},{"issue":"2","key":"13242_CR27","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1097\/IGC.0b013e3182070f17","volume":"21","author":"GJ Rustin","year":"2011","unstructured":"Rustin GJ, Vergote I, Eisenhauer E, Pujade-Lauraine E, Quinn M, Thigpen T, Gynecological Cancer Intergroup, et al. Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer. 2011;21(2):419\u201323. https:\/\/doi.org\/10.1097\/IGC.0b013e3182070f17.","journal-title":"Int J Gynecol Cancer"},{"issue":"54","key":"13242_CR28","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.21105\/joss.02630","volume":"5","author":"V Alcazer","year":"2020","unstructured":"Alcazer V. StatAid: an R package with a graphical user interface for data analysis. J Open Source Softw. 2020;5(54):2630. https:\/\/doi.org\/10.21105\/joss.02630.","journal-title":"J Open Source Softw"},{"issue":"4","key":"13242_CR29","first-page":"2315","volume":"35","author":"N Bacalbasa","year":"2015","unstructured":"Bacalbasa N, Balescu I, Dima S, Herlea V, David L, Brasoveanu V, et al. Initial incomplete surgery modifies prognosis in advanced ovarian cancer regardless of subsequent management. Anticancer Res. 2015;35(4):2315\u201320.","journal-title":"Anticancer Res."},{"issue":"2","key":"13242_CR30","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1002\/jso.20676","volume":"95","author":"PH Sugarbaker","year":"2007","unstructured":"Sugarbaker PH. Peritoneum as the first-line of defense in carcinomatosis. J Surg Oncol. 2007;95(2):93\u20136. https:\/\/doi.org\/10.1002\/jso.20676.","journal-title":"J Surg Oncol."},{"key":"13242_CR31","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s11912-001-0037-0","volume":"3","author":"CS Chu","year":"2001","unstructured":"Chu CS, Rubin SC. Second-look laparotomy for epithelial ovarian cancer: a reappraisal. Curr Oncol Rep. 2001;3:11\u20138. https:\/\/doi.org\/10.1007\/s11912-001-0037-0.","journal-title":"Curr Oncol Rep"},{"issue":"7","key":"13242_CR32","doi-asserted-by":"publisher","first-page":"756","DOI":"10.4251\/wjgo.v12.i7.756","volume":"12","author":"JL Leiting","year":"2020","unstructured":"Leiting JL, Cloyd JM, Ahmed A, Fournier K, Lee AJ, Dessureault S, et al. Comparison of open and closed hyperthermic intraperitoneal chemotherapy: results from the United States hyperthermic intraperitoneal chemotherapy collaborative. World J Gastrointest Oncol. 2020;12(7):756\u201367. https:\/\/doi.org\/10.4251\/wjgo.v12.i7.756.","journal-title":"World J Gastrointest Oncol"},{"issue":"2","key":"13242_CR33","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/S1470-2045(20)30599-4","volume":"22","author":"F Qu\u00e9net","year":"2021","unstructured":"Qu\u00e9net F, Elias D, Roca L, Go\u00e9r\u00e9 D, Ghouti L, Pocard M, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(2):256\u201366. https:\/\/doi.org\/10.1016\/S1470-2045(20)30599-4.","journal-title":"Lancet Oncol"},{"issue":"5","key":"13242_CR34","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1080\/02656736.2017.1367846","volume":"34","author":"M Alyami","year":"2018","unstructured":"Alyami M, Kim BJ, Villeneuve L, Vaudoyer D, K\u00e9p\u00e9n\u00e9kian V, Bakrin N, et al. Ninety-day post-operative morbidity and mortality using the National Cancer Institute\u2019s common terminology criteria for adverse events better describe post-operative outcome after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Int J Hyperthermia. 2018;34(5):532\u20137. https:\/\/doi.org\/10.1080\/02656736.2017.1367846.","journal-title":"Int J Hyperthermia"},{"key":"13242_CR35","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1097\/01.sla.0000218089.61635.5f","volume":"244","author":"P Esquis","year":"2006","unstructured":"Esquis P, Consolo D, Magnin G, Pointaire P, Moretto P, Ynsa MD. High intra-abdominal pressure enhances the penetration and antitumor effect of intraperitoneal cisplatin on experimental peritoneal carcinomatosis. Ann Surg. 2006;244:106\u201312.","journal-title":"Ann Surg"},{"issue":"1","key":"13242_CR36","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.ejso.2019.06.022","volume":"47","author":"S Kusamura","year":"2021","unstructured":"Kusamura S, Azmi N, Fumagalli L, Baratti D, Guaglio M, Cavalleri A, et al. Phase II randomized study on tissue distribution and pharmacokinetics of cisplatin according to different levels of intra-abdominal pressure (IAP) during HIPEC (NCT02949791). Eur J Surg Oncol. 2021;47(1):82\u20138. https:\/\/doi.org\/10.1016\/j.ejso.2019.06.022.","journal-title":"Eur J Surg Oncol"},{"issue":"2","key":"13242_CR37","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.ygyno.2021.01.039","volume":"161","author":"LM Chambers","year":"2021","unstructured":"Chambers LM, Yao M, Morton M, Gruner M, Chichura A, Horowitz M, et al. Patterns of recurrence in women with advanced and recurrent epithelial ovarian cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Gynecol Oncol. 2021;161(2):389\u201395. https:\/\/doi.org\/10.1016\/j.ygyno.2021.01.039.","journal-title":"Gynecol Oncol"},{"issue":"6","key":"13242_CR38","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1016\/j.ejso.2021.01.013","volume":"47","author":"S Sinukumar","year":"2021","unstructured":"Sinukumar S, Damodaran D, Ray M, Mehta S, Paul L, Bhatt A. Pattern of recurrence after interval cytoreductive surgery and HIPEC following neoadjuvant chemotherapy in primary advanced stage IIIC\/IVA epithelial ovarian cancer. Eur J Surg Oncol. 2021;47(6):1427\u201333. https:\/\/doi.org\/10.1016\/j.ejso.2021.01.013.","journal-title":"Eur J Surg Oncol"},{"issue":"2","key":"13242_CR39","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.ygyno.2020.08.028","volume":"159","author":"H Plett","year":"2020","unstructured":"Plett H, Filippova OT, Garbi A, Kommoss S, Rosendahl M, Langstraat C, et al. Role of delayed interval debulking for persistent residual disease after more than 5 cycles of chemotherapy for primary advanced ovarian cancer. An international multicenter study. Gynecol Oncol. 2020;159(2):434\u201341. https:\/\/doi.org\/10.1016\/j.ygyno.2020.08.028.","journal-title":"Gynecol Oncol"},{"issue":"12","key":"13242_CR40","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1136\/ijgc-2020-001641","volume":"30","author":"YL Liu","year":"2020","unstructured":"Liu YL, Zhou QC, Iasonos A, Chi DS, Zivanovic O, Sonoda Y, et al. Pre-operative neoadjuvant chemotherapy cycles and survival in newly diagnosed ovarian cancer: what is the optimal number? A Memorial Sloan Kettering Cancer Center Team Ovary study. Int J Gynecol Cancer. 2020;30(12):1915\u201321. https:\/\/doi.org\/10.1136\/ijgc-2020-001641.","journal-title":"Int J Gynecol Cancer"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-023-13242-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-023-13242-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-023-13242-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T23:06:30Z","timestamp":1683846390000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-023-13242-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,23]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["13242"],"URL":"https:\/\/doi.org\/10.1245\/s10434-023-13242-8","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,23]]},"assertion":[{"value":"23 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Olivier Glehen is a consultant for GamidaTech. Jean-Marc Classe declares associations with GSK, Myriad, MSD, and Clovis for expertise on surgical oncology. Lisa Frankinet, Aditi Bhatt, Vincent Alcazer, Jean-Marc Bereder, Pierre Meeus, Christophe Pomel, Francois Mithieux, Karine Abboud, Romauld Wermert, Vincent Lavoue, Frederic Marchal, and Naoual Bakrin have no disclosures or conflicts of interest to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}